DataMeds AI, Inc. (NASDAQ:MEDS) has outlined plans to expand into the peptide compounding market through its pharmacy subsidiary, Corexa Health, following a proposed policy change by the U.S. Food and Drug Administration (FDA).
The company said the FDA’s proposed “Interim Access Policy for Compounding Using Certain Peptides” could create opportunities for its pharmacy, distribution and healthcare technology operations.
The announcement follows a recommendation by the FDA’s Pharmacy Compounding Advisory Committee (PCAC), made less than three months earlier, to ease restrictions affecting six peptides.
DataMeds intends to use Corexa Health’s existing infrastructure to support prescription dispensing, pharmaceutical distribution and technology services if the proposed regulatory changes take effect.
FDA Proposal Creates Potential Opportunities in Peptide Compounding
The FDA’s proposed interim policy addresses access to certain peptides used in pharmaceutical compounding.
The proposal follows the PCAC’s recommendation to relax restrictions on six peptide substances, potentially changing the conditions under which eligible compounding pharmacies can prepare medications containing those ingredients.
DataMeds said the regulatory development has prompted Corexa Health to prepare for participation in the market.
However, the proposed policy has not yet taken effect, and the company’s planned dispensing activities remain dependent on the applicable regulatory requirements.
According to market research firm Precedence Research, the US compounding pharmacy market is projected to increase from approximately $18 billion in 2025 to more than $34 billion annually by 2035.
These estimates cover the broader compounding pharmacy market rather than peptide products alone.
DataMeds identified the potential expansion of this market as an opportunity for its existing healthcare businesses.
Corexa Pharmacy Prepares to Dispense Peptide Prescriptions
Corexa Pharmacy, the company’s 503A compounding pharmacy division, intends to begin filling eligible peptide prescriptions once the FDA’s interim policy becomes effective.
Section 503A of the Federal Food, Drug, and Cosmetic Act establishes conditions under which qualifying pharmacies may compound medications for individual patients pursuant to valid prescriptions.
Corexa Pharmacy plans to operate within the applicable regulatory framework as it develops its peptide-related services.
The company said it has already started evaluating potential suppliers of pharmaceutical substances that could be used in peptide compounding.
It expects to finalise supplier agreements within the coming weeks.
These preparations are intended to establish the sourcing arrangements necessary to support prescription fulfilment if the proposed policy is implemented.
DataMeds did not disclose the expected revenue contribution, initial prescription volumes or financial investment associated with the planned expansion.
Corexa Distribution Targets Independent Pharmacies Across the US
Corexa Distribution, another division of Corexa Health, plans to supply peptide drug substances to independent pharmacies.
The business is licensed in all 50 US states and operates a 40,000-square-foot warehouse in Lakeland, Florida.
DataMeds intends to use this distribution infrastructure to support pharmacies seeking access to eligible peptide ingredients.
In addition to pharmaceutical distribution, Corexa Distribution plans to provide third-party logistics services to peptide manufacturers.
These services would allow manufacturers to use Corexa’s warehousing and distribution capabilities rather than relying exclusively on their own logistics operations.
The proposed expansion would give Corexa Health a role in supplying pharmacies as well as dispensing prescriptions through its own pharmacy business.
The company has not announced specific distribution contracts or identified manufacturers that have committed to using the service.
Corexa Tech & Hub to Support Prescription Routing and Insurance Verification
Corexa Health’s third division, Corexa Tech & Hub, provides technology services connecting healthcare providers, pharmacies and patients.
The platform routes prescriptions issued by physicians to Corexa Pharmacy or to a local pharmacy selected by the patient.
DataMeds intends to use this capability to support the processing of eligible peptide prescriptions as the business expands.
The division also offers an Electronic Benefits Verification service designed to monitor changes in insurance coverage for peptide-related treatments.
The service is intended to provide information about insurance benefits and coverage status, although coverage will depend on individual insurance policies and the products involved.
By combining prescription routing with pharmacy and distribution operations, DataMeds aims to establish a coordinated service model for its planned peptide business.
DataMeds Identifies Patients Using Unregulated Supply Channels as Initial Market
Gerald Commissiong, Interim Co-Chief Executive Officer of DataMeds, said the company intends to initially market its peptide offerings to patients who have historically obtained these products through what he described as the grey market.
The proposed approach would focus on patients who may be seeking access to peptide products through prescription-based pharmacy channels.
However, the availability of compounded peptide medications will remain subject to FDA requirements, applicable state regulations and the professional judgement of prescribing healthcare providers.
The company’s plans do not establish that all peptides currently obtained through alternative channels will become eligible for lawful compounding.
DataMeds has not provided a timetable for the commercial launch of its peptide services beyond the anticipated supplier agreements and the proposed FDA policy’s implementation.
Company Expands GLP-1 Technology Programmes Through REBOOT Agreement
Alongside its peptide compounding plans, DataMeds said it recently licensed technology from REBOOT for programmes involving patients who use FDA-approved GLP-1 receptor agonist medications.
GLP-1 receptor agonists are a class of medicines used in certain approved treatments, including for diabetes and weight management.
The company is developing related services through its Health Lives Here mobile application.
The announcement did not provide financial terms for the REBOOT licensing agreement or detailed information about the planned commercial rollout.
The initiative represents a separate healthcare technology development alongside Corexa Health’s proposed peptide compounding and distribution activities.
DataMeds Maintains Laboratory Operations Through Helomics
DataMeds AI is headquartered in Tampa, Florida, and operates healthcare businesses spanning pharmacy services, technology and laboratory testing.
In addition to Corexa Health, the company owns Helomics Corporation, a CLIA-certified laboratory based in Pittsburgh.
Helomics provides the ChemoFx Assay, a laboratory service associated with cancer treatment assessment.
The laboratory business forms part of DataMeds’ broader healthcare operations as the company explores additional opportunities in pharmaceutical services and patient-focused technology.
Regulatory Implementation Remains Key to Expansion Plans
DataMeds’ proposed entry into peptide compounding will depend on the final regulatory conditions established by the FDA and the company’s ability to secure appropriate suppliers and operational arrangements.
Corexa Health’s three divisions provide existing infrastructure for prescription dispensing, nationwide distribution and healthcare technology services.
However, the company has not disclosed financial forecasts, expected sales volumes or specific revenue targets for the peptide initiative.
The FDA’s proposed interim access policy remains the principal near-term development affecting the planned expansion.
Investors will be monitoring the regulatory process, the completion of supplier agreements and any subsequent announcements regarding the commercial launch of Corexa Health’s peptide-related services.